Prevalence of Endolymphatic Hydrops With a Hitory of Congenital Cytomegalovirus Infection (HYDROPS-CMV)

Fondation Ophtalmologique Adolphe de Rothschild

Status: Terminated

Conditions: Endolymphatic Hydrops

Treatments: Device: sequence MRI 3D FLAIR

Study type: Observational

Funder types: NETWORK

Identifiers

NCT05229744

GPN_2021_23

Details and patient eligibility

About

The management of patients with a history of congenital CMV infection (whether symptomatic or asymptomatic at birth) is modeled on their usual management.

Full description

The management of patients with a history of congenital CMV infection (whether symptomatic or asymptomatic at birth) is modeled on their usual management.

Patients benefit as part of the care:

• A clinical cochleo-vestibular examination
• Functional otoneurological explorations: audiogram, caloric tests, vHIT, otolithic evoked potentials
• From an uninjected brain MRI

Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®):

- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product.

Enrollment: 18 patients

Sex: All

Ages: 6+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient over 6 months old
• With a history of confirmed congenital CMV infection
• Suffering from symptomatic cochleo-vestibular dysfunction (average hearing threshold> 20dB in at least one ear and / or abnormal functioning of one or more sectors at the vestibular level)
• For adult patients, having received informed information about the study and having signed a consent to participate in the study
• For minor patients written consent of the two holders of the exercise of parental authority
• Affiliate or beneficiary of a social security scheme

Exclusion criteria

• Patient benefiting from a legal protection measure
• Pregnant or breastfeeding woman
• Contraindication to MRI (implanted electrical device, metallic foreign body, claustrophobia)
• Patient with a proven allergy to gadolinium
• Injection of gadolinium in the previous 7 days
• Known impairment of renal function ((estimated GFR <60 mL / min / 1.73 m²)